Merck KGaA gets green light on lung cancer vax trials

Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial contracted encephalitis in March. Licensed from Oncothyreon, the German pharma company has made a committed effort to bring in a trove of late-stage data on a range of cancers for its closely-watched therapeutic vaccine. Investigators now have an approval to ramp the lung cancer trials back up while leaving the breast cancer trial on hold for now. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.